Glioblastomas, classified as grade IVastrocytomas, are among the most aggressive and frequently occurring primary brain tumors in adults. Patients withglioblastomashave an extremely poor prognosis: with a 5-yearsurvival rateof 1%, the currently available treatments of surgery,radiation therapy, and che...
SurvivalBrain tumorsTreatmentRadiotherapyThis paper presents an atypical case of a patient with brain tumor of the glioblastoma multiforme (GBM) type who achieved a 5-year survival. Some general information is provided including epidemiology, diagnostic and treatment procedures (surgery and radio-chemo-...
Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite comprehensive treatment with traditional surgery, radiotherapy, and chemotherapy, the median survival rate is <14.6% and the 5-year survival rate is only 5%. FBXO22, a substrate receptor of the SCF ubiquitin ligases, ha...
The two-year survival rate was26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapyalone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3or 4 hematologic toxic effects in 7 percent of patients. conclusions The addition of temozolomide to ...
Glioblastoma (GBM) represents the most common and aggressive form of malignant tumor in the central nervous system, characterized by a low five-year survival rate of 6.8%1. Despite advancements in diagnostic techniques and treatment modalities, therapeutic resistance and tumor recurrence continue to cha...
Their clinical behaviors are almost as aggressive as those in adults, and the 5-year overall survival rate is poor.Wei ZhangYi LinBaoshi ChenSonya Wei SongTao JiangChild's Nervous SystemZhang W,Lin Y,Chen B,etc.Recurrent glioblastoma of childhood treated with bevacizumab: case report and ...
Glioblastoma (GB) accounts for 47.7% of all CNS malignant tumors in adults, and patients have a median overall survival (OS) of only eight months and a 5-year survival of 5.8% (95% CI 5.5–6.1).1 The incidence of GB is low compared to that of other tumors, but there is ...
For the patient in IV stage of glioblastoma multiforme, the rate of survival diminishes. With treatment, the patient can hardly live two years as the disease is not curable. In this stage, the tumor travels and spreads in another part of the body. In generally the life expectancy of the ...
However, despite the critical advancements in diagnostic tools and surgical techniques over the most recent two decades, no conspicuous enhancements have been accomplished in survival results starkly contrasted with other gliomas, with a 5-year survival estimate of only 9.8% in the most optimistic ...
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009). Article CAS PubMed Google Scholar Cohen, K. J. et al. ...